HAS Authority Over Cancer Program Become Hot Issues; Fredrickson Opposes Exemption For NCI
In Brief: Cancer Claims Morris Kupchan, Who Found Promising New Antitumor Drugs In Plants
L-PAM Benefit To Post-Menopausal Patients Challenged
NCI Relates FDA Instructions On Latest IND Delays
Two Workshops To Look For New Research Areas
Proposed Regulations for Center Grants In Federal Register
Obey Attacks NCI In Campaign Speech
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- FDA’s OCE publishes three final guidances to increase clinical trial enrollment
